---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-095094"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:48:26.945660+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports FY2025 net loss of $77.7M; reaffirms NDA filing for rezatapopt in Q1 2027

## Summary
- Cash and securities $112.9M at Dec 2025 (down from $183.3M); runway to end of Q2 2027.
- Net loss $77.7M for FY2025 vs $58.7M in 2024; net cash used in ops $73.6M (vs $51.3M).
- R&D expenses $69.9M (up from $58.5M) on rezatapopt trial costs; G&A $16.3M (down from $26.9M).
- PYNNACLE Phase 2 enrollment on track; NDA submission for ovarian cancer planned Q1 2027.
- Rezatapopt granted FDA Orphan Drug Designation for TP53 Y220C positive ovarian cancer; Phase 1 in NEJM.

## SEC filing metadata
- accession: 0001193125-26-095094
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/0001193125-26-095094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/pmvp-20260306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-095094
- JSON: https://secwatch.observer/filing/0001193125-26-095094.json
- Plain text: https://secwatch.observer/filing/0001193125-26-095094.txt

## Key facts
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported the full year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $77.7 million.
  - Period: the full year ended December 31, 2025
  - Net income: Net loss for the year ended December 31, 2025, was $77.7 million
  - Result: reported results
  source text: On March 6, 2026, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/0001193125-26-095094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.